Oral medications serve as the cornerstone for treating T2DM, whereas injectable options, including insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are implemented for both type 1 diabetes mellitus (T1DM) and more advanced stages of T2DM. This evidence concerns the gene INS and type 2 diabetes mellitus.